Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.48 |
| ▸ | INSR | P06213 | 5/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281514 | 1.00 | AURKB (0.54) | AURKBKDRAURKAALKINSR | |
| SCHEMBL4280244 | 0.90 | AURKA (0.50) | AURKBKDRAURKASYKLCK | |
| SCHEMBL578939 | 0.90 | AURKA (0.50) | AURKBKDRAURKASYKLCK | |
| SCHEMBL579158 | 0.86 | PTK2 (0.57) | AURKAALKJAK3GSK3BGSK3A | |
| SCHEMBL13817628 | 0.86 | AURKA (0.44) | AURKBKDRAURKASYKLCK | |
| SCHEMBL2526061 | 0.86 | PTK2 (0.57) | AURKAALKJAK3GSK3BGSK3A | |
| SCHEMBL10149253 | 0.86 | PTK2 (0.57) | AURKAALKJAK3GSK3BGSK3A | |
| SCHEMBL13817490 | 0.86 | AURKA (0.44) | AURKBKDRAURKASYKLCK | |
| SCHEMBL13313530 | 0.86 | KDR (0.51) | AURKBKDRALKINSRSYK | |
| SCHEMBL578750 | 0.84 | SYK (0.50) | AURKBKDRALKINSRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623887-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2027107-B1 | 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20090163467-A1 | New compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163467-A1 | New compounds | CCNA1, MKI67, CCNT1 | AURKB 1454/4885KDR 1793/4885AURKA 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.